TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07635186: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B.

Sponsor: Ausper Biopharma Co., Ltd. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 320 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,145,000

Rescue Site Savings

+$3,410,400

Unlock Full NCT07635186 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07635186 Rescue Dossier →